产品
编 号：F178254
分子式：C28H43N7O7
分子量：589.68
分子式：C28H43N7O7
分子量：589.68
产品类型
规格
价格
是否有货
结构图
CAS No: 151276-95-8
产品详情
生物活性：
KRN5500 (NSC 650426), a Spicamycin (HY-127130) derivative and a nucleoside-like antibiotic with anti-tumor activity. KRN5500 also induces apoptosis via the down-regulation of Bcl-2 expression. KRN5500 shows a significant efficacy in the human tumor xenograft model in mice.
体内研究：
KRN5500 (4 mg/kg; 腹腔注射; 每天 1 次，共 5 天) 显示抗肿瘤活性，导致一些小鼠肿瘤和人肿瘤异种抑制模型中的肿瘤重量下降。Animal Model:Mouse model with murine tumors and human tumor xenografts
Dosage:4 mg/kg
Administration:Intraperitoneal injection; once daily for 5 days
Result:Prolonged the survival of P388 leukemia- and B16 melanoma-bearing mice but lacked marginally effective on colon adenocarcinoma.Decreased tumor weight in 10 human stomach, 14 colon and 2 esophageal cancers.
体外研究：
KRN5500 (10-160 ng/mL; 0-5 d) 有效抑制 NB4、NKM-1 和 HL-60 细胞的增殖和活力。KRN5500 (40 ng/mL, 160 ng/mL; 48 h) 诱导 NB4、HL-60 和 NKM-1 细胞凋亡。KRN5500 (40 ng /mL, 80 ng /mL; 36 h) 下调 NB4 细胞中 Bcl-2 的表达。
KRN5500 (NSC 650426), a Spicamycin (HY-127130) derivative and a nucleoside-like antibiotic with anti-tumor activity. KRN5500 also induces apoptosis via the down-regulation of Bcl-2 expression. KRN5500 shows a significant efficacy in the human tumor xenograft model in mice.
体内研究：
KRN5500 (4 mg/kg; 腹腔注射; 每天 1 次，共 5 天) 显示抗肿瘤活性，导致一些小鼠肿瘤和人肿瘤异种抑制模型中的肿瘤重量下降。Animal Model:Mouse model with murine tumors and human tumor xenografts
Dosage:4 mg/kg
Administration:Intraperitoneal injection; once daily for 5 days
Result:Prolonged the survival of P388 leukemia- and B16 melanoma-bearing mice but lacked marginally effective on colon adenocarcinoma.Decreased tumor weight in 10 human stomach, 14 colon and 2 esophageal cancers.
体外研究：
KRN5500 (10-160 ng/mL; 0-5 d) 有效抑制 NB4、NKM-1 和 HL-60 细胞的增殖和活力。KRN5500 (40 ng/mL, 160 ng/mL; 48 h) 诱导 NB4、HL-60 和 NKM-1 细胞凋亡。KRN5500 (40 ng /mL, 80 ng /mL; 36 h) 下调 NB4 细胞中 Bcl-2 的表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备